To amend the Public Health Service Act to establish an Office of Drug Manufacturing.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To amend the Public Health Service Act to establish an Office of Drug Manufacturing., changes federal law or congressional policy affecting federal agencies and legislative administrators. The main policy domain is Government Operations, Healthcare, Trade.
Who Benefits and How
federal agencies and legislative administrators may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H49FB9D3006CE45D1B98625EA6341B2DD: 1. Short title This Act may be cited as the Affordable Drug Manufacturing Act of 2023.
- Section H14A4ABD8C87942B2B84FCED14A8F1A3E: 2. Public manufacturing of pharmaceuticals Part A of title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by adding at the end the...
- Section H1328DBF52E7D4C339812D68B0D5B8713: 310C. Manufacturing of drugs There is established within the Department of Health and Human Services an office to be known as the Office of Drug Manufacturing...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To amend the Public Health Service Act to establish an Office of Drug Manufacturing., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Key Policy Areas
Government Operations, Healthcare, Trade
Primary Purpose
This bill, To amend the Public Health Service Act to establish an Office of Drug Manufacturing., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Policy Domains
Whole bill
Identified Gains
- federal agencies and legislative administrators
Identified Costs
- federal implementing agencies
Sponsors
Legislative Progress
IntroducedMs. Schakowsky (for herself, Ms. Lee of California, Mr. Jackson …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
Key Definitions
Terms defined in this bill
any entity that is currently— a drug manufacturer
any entity that is currently— a drug manufacturer
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology